Self-assembled polymeric micelle as a novel mRNA delivery carrier

Ren, Jin; Cao, Yiming; Li, Lei; Wang, Xin; Lü, Haitao; Yang, Jing; Wang, Shengqi

doi:10.1016/j.jconrel.2021.08.061

Cited by 55 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The in vitro results proved that modification with vitamin E significantly reduced the cytotoxicity of naïve PEI. Moreover, this self-assembled polymeric micelle delivery system containing SARS-CoV-2 RBD mRNA showed an increased amount of antigen-specific antibody IgG and substantial T-cell response against SARS-CoV-2 RBD antigen after administration in vivo [60]. In another study, the difference between extracellular and intracellular ATP concentration was utilized to achieve efficient cargo release from polyplex micelles.…”

Section: Applications For Vaccinationmentioning

confidence: 98%

Advances in Nanoparticles for Effective Delivery of RNA Therapeutics

et al. 2022

View full text Add to dashboard Cite

RNA therapeutics, including messenger RNA (mRNA) and small interfering RNA (siRNA), are genetic materials that mediate the translation of genetic direction from genes to induce or inhibit specific protein production. Although the interest in RNA therapeutics is rising globally, the absence of an effective delivery system is an obstacle to the clinical application of RNA therapeutics. Additionally, immunogenicity, short duration of protein expression, unwanted enzymatic degradation, and insufficient cellular uptake could limit the therapeutic efficacy of RNA therapeutics. In this regard, novel platforms based on nanoparticles are crucial for delivering RNAs to the targeted site to increase efficiency without toxicity. In this review, the most recent status of nanoparticles as RNA delivery vectors, with a focus on polymeric nanoparticles, peptidederived nanoparticles, inorganic nanoparticles, and hybrid nanoparticles, is discussed. These nanoparticular platforms can be utilized for safe and effective RNA delivery to augment therapeutic effects. Ultimately, RNA therapeutics encapsulated in nanoparticle-based carriers will be used to treat many diseases and save lives.

show abstract

Section: Applications For Vaccinationmentioning

confidence: 98%

Advances in Nanoparticles for Effective Delivery of RNA Therapeutics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…PVES micelles showed high transfection efficiency in four cell lines, i.e., HEK-293T, HeLa, Vero, and DC2.4 cells, without significant cytotoxicity. The PVES/mRNA vaccine was shown to trigger antigen-specific CD8+ T cells (Th1 cells) expressing the type 1 immune response cytokine, IFN-γ, and CD4+ T cells expressing the type II cytokine, IL-4 ( 49 ). They also assessed the safety of the mRNA vaccine with PVES as a vector.…”

Section: Mrna Delivery Systemsmentioning

confidence: 99%

“…They also assessed the safety of the mRNA vaccine with PVES as a vector. No local inflammatory reactions or other adverse effects at the injection site were observed during the observation period after immunization ( 49 ).…”

Section: Mrna Delivery Systemsmentioning

confidence: 99%

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy

Deng

Tian²,

Song³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vaccines, and there has been a great deal of interest in the research and development of mRNA cancer vaccines. There has been progress in a number of key technologies, including mRNA production strategies, delivery systems, antitumor immune strategies, etc. These technologies have accelerated the progress and clinical applications of mRNA therapy, overcoming problems encountered in the past, such as instability, inefficient delivery, and weak immunogenicity of mRNA vaccines. This review provides a detailed overview of the production, delivery systems, immunological mechanisms, and antitumor immune response strategies for mRNA cancer vaccines. We list some mRNA cancer vaccines that are candidates for cancer treatment and discuss clinical trials in the field of tumor immunotherapy. In addition, we discuss the immunological mechanism of action by which mRNA vaccines destroy tumors as well as challenges and prospects for the future.

show abstract

“…Other novel delivery strategies introduced during the COVID-19 pandemic and with the broader aim of overcoming the limitations of existing delivery systems included self-assembled polymeric micelle delivery systems based on polyethyleneimine modified with vitamin E succinate ( Ren et al, 2021a ). A PVES/mRNA vaccine encoding the SARS-CoV-2 RBD antigen was shown to induce a Th1-type immune response, with no inflammatory reaction at the injection site and no significant lesions in other vital organs ( Ren et al, 2021a ).…”

Section: Sequence Construction and Delivery Optimization Of Mrna Vacc...mentioning

confidence: 99%

mRNA vaccines: A novel weapon to control infectious diseases

2022

View full text Add to dashboard Cite

Infectious diseases have always threatened human life, but with the development of vaccines, effective strategies for preventing and controlling these diseases have become available. The global outbreak of COVID-19 ushered in the advent of mRNA vaccine technologies, which quickly led to the introduction of mRNA vaccines effective against SARS-CoV-2. The success of this approach has stimulated research into the use of mRNA vaccines in the fight against other emerging as well as remerging infectious diseases. This review examines the constructive strategies and delivery systems used in mRNA vaccines and provides an overview of current clinical trials of those vaccines in the prevention of infectious diseases. The underlying mechanisms of mRNA vaccines are also discussed, including the double-edged sword of the innate immune response. Finally, the challenges but also the potential of mRNA vaccines are considered.

show abstract

Self-assembled polymeric micelle as a novel mRNA delivery carrier

Cited by 55 publications

References 34 publications

Advances in Nanoparticles for Effective Delivery of RNA Therapeutics

Advances in Nanoparticles for Effective Delivery of RNA Therapeutics

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy

mRNA vaccines: A novel weapon to control infectious diseases

Contact Info

Product

Resources

About